COYACoya Therapeutics, Inc.
Earnings
When Coya Therapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.
19 quarters. Mar 31, 2022 to Sep 30, 2026. USD.
Next results · Q4 2026Projected
Mar 15, before the open
Mon, Mar 15, 2027in 118 days
Projected from its last 8 releases. The company has not named the day yet.
- Quarter
- Q4 2026 · Ends about Dec 31, 2026
- 10-K window
- Mar 15 – Apr 1
Read against Q4 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- $3.96M
- Revenue, change from a year earlier: Q3 2026 −93.4%, Q2 2026 +49.0%, Q1 2026 −2.6%, Q4 2025 +202,768.8%
- Net income
- -$5.71M
- Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
- EPS
- —
- EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m
Latest results
- Revenue
- $234.13K
- −93.4%
- Net income
- -$10.62M
- N/M
- EPS
- -$0.45
- N/M
Read · nothing to show- Revenue
- $243.75K
- +49.0%
- Net income
- -$6.64M
- N/M
- EPS
- -$0.28
- N/M
- Revenue
- $251.15K
- −2.6%
- Net income
- -$7.21M
- N/M
- EPS
- -$0.32
- N/M
- Revenue
- $3.96M
- +202,768.8%
- Net income
- -$5.71M
- N/M
- EPS
- —
- —
All quarters
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Move | Source trail |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2026 | ||||||||||
| Q3 2026 | Sep 30, 2026 | Nov 10, 2026 · pre-market | Nov 10, 2026 | 41 d | 10-Q | $234.13K | −93.4% | -$0.45 | 5.3% | |
| Q2 2026 | Jun 30, 2026 | Aug 11, 2026 · pre-market | Aug 11, 2026 | 42 d | 10-Q | $243.75K | +49.0% | -$0.28 | +3.8% | |
| Q1 2026 | Mar 31, 2026 | May 12, 2026 · pre-market | May 12, 2026 | 42 d | 10-Q | $251.15K | −2.6% | -$0.32 | +2.9% | |
| FY 2025 | ||||||||||
| Q4 2025derived | Dec 31, 2025 | Mar 16, 2026 · pre-market | Mar 16, 2026 | 75 d | 10-K | $3.96M | +202,768.8% | — | 0.8% | |
| Q3 2025 | Sep 30, 2025 | Nov 12, 2025 · pre-market | Nov 12, 2025 | 43 d | 10-Q | $3.56M | — | -$0.13 | +0.5% | |
| Q2 2025 | Jun 30, 2025 | Aug 12, 2025 · pre-market | Aug 12, 2025 | 43 d | 10-Q | $163.62K | −95.2% | -$0.36 | 1.0% | |
| Q1 2025 | Mar 31, 2025 | May 13, 2025 · pre-market | May 13, 2025 | 43 d | 10-Q | $257.88K | +103.3% | -$0.44 | 5.6% | |
| FY 2024 | ||||||||||
| Q4 2024derived | Dec 31, 2024 | Mar 18, 2025 · pre-market | Mar 18, 2025 | 77 d | 10-K | $1.95K | −100.0% | — | 3.9% | |
| Q3 2024 | Sep 30, 2024 | Nov 6, 2024 · pre-market | Nov 6, 2024 | 37 d | 10-Q | $0.00 | — | -$0.26 | +6.9% | |
| Q2 2024 | Jun 30, 2024 | Aug 12, 2024 · pre-market | Aug 12, 2024 | 43 d | 10-Q | $3.43M | — | -$0.19 | — | |
| Q1 2024 | Mar 31, 2024 | May 9, 2024 · after-hours | May 9, 2024 | 39 d | 10-Q | $126.84K | — | -$0.35 | 3.0% | |
| FY 2023 | ||||||||||
| Q4 2023derived | Dec 31, 2023 | Mar 19, 2024 · pre-market | Mar 19, 2024 | 79 d | 10-K | $6.00M | — | — | +2.1% | |
| Q3 2023 | Sep 30, 2023 | Nov 8, 2023 · pre-market | Nov 8, 2023 | 39 d | 10-Q | $0.00 | — | -$0.34 | 3.6% | |
| Q2 2023 | Jun 30, 2023 | Aug 8, 2023 · pre-market | Aug 8, 2023 | 39 d | 10-Q | $0.00 | — | -$0.31 | +0.5% | |
| Q1 2023 | Mar 31, 2023 | May 10, 2023 · pre-market | May 10, 2023 | 40 d | 10-Q | $0.00 | — | -$0.28 | 2.8% | |
| FY 2022 | ||||||||||
| Q4 2022derived | Dec 31, 2022 | Mar 29, 2023 · after-hours | Mar 29, 2023 | 88 d | 10-K | — | — | — | 5.0% | |
| Q3 2022 | Sep 30, 2022 | — | — | — | — | — | — | -$1.55 | — | |
| Q2 2022 | Jun 30, 2022 | — | — | — | — | — | — | -$1.32 | — | |
| Q1 2022 | Mar 31, 2022 | — | — | — | — | — | — | -$0.66 | — | |
Earlier years, FY 2022 to FY 2023The latest three years
Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Source filings
Provenance
ProvenanceData status and checks
Coya Therapeutics, Inc. · CIK 1835022 · Engraved from SEC EDGAR